I et ikke - placebokontrolleret, randomiseret studie blev 817 tidligere ubehandlede patienter med CLL randomiseret til enten FC- kemoterapi (fludarabin 25mg/ m2, cyclophosphamid 250 mg/ m2, på dag 1- 3) hver 4. uge i 6 serier eller MabThera i kombination med FC (R- FC).
In an open-label randomized trial, a total of 817 previously untreated patients with CLL were randomized to receive either FC chemotherapy (fludarabine 25 mg/ m2, cyclophosphamide 250 mg/ m2, days 1-3) every 4 weeks for 6 cycles or MabThera in combination with FC (R-FC).